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Introduction: The aim of this study was to investigate the expression of tumor necrosis factor-like weak inducer of
apoptosis (TWEAK) and its receptor fibroblast growth factor-inducible 14 (Fn14) in patients with polymyositis (PM)
and dermatomyositis (DM), and their relation to clinical manifestations.
Methods: Serum levels of TWEAK were detected in 98 PM/DM patients and 37 healthy controls by using the ELISA
method. Total RNA isolated from fresh-frozen muscle tissue samples of 36 PM/DM patients and 10 healthy controls
were used for analyzing the mRNA levels of TWEAK and Fn14 by quantitative reverse transcription polymerase chain
reaction (RT-PCR). Immunofluorescence staining of TWEAK and Fn14 was conducted on muscle biopsy specimens
from 23 PM/DM patients and seven healthy controls.
Results: Serum levels of TWEAK were significantly decreased in the PM/DM patients compared to those in the
healthy controls (P < 0.001), and serum TWEAK levels negatively correlated with serum CD163 levels in PM/DM
patients (r = -0.49, P < 0.001). The expression of Fn14 mRNA was significantly increased in the muscle tissue of PM/
DM patients than in the muscle tissue of healthy controls (P < 0.01), whereas the expression of TWEAK mRNA in
PM/DM patients was not statistically different from that of the healthy controls (P > 0.05). Fn14 mRNA levels in
muscle tissue positively correlated with muscle disease activity (r = 0.512, P < 0.01). Patients with oropharyngeal
dysphagia had significantly higher Fn14 mRNA levels than patients without oropharyngeal dysphagia (P < 0.05).
The results of immunofluorescence staining showed that 19 out of 23 PM/DM patients were TWEAK-positive, and
20 out of 23 PM/DM patients were Fn14-positive. No detectable expressions of TWEAK or Fn14 were observed in
the healthy controls.
Conclusions: TWEAK-Fn14 axis may be involved in the pathogenesis of PM/DM. Further understanding of
TWEAK-Fn14 function in PM/DM may help to define therapeutic targets for PM/DM.Introduction
Idiopathic inflammatory myopathies (IIM) are a hetero-
geneous group of muscle disorders characterized by sym-
metrical proximal muscle weakness, decreased muscle
endurance, and inflammatory infiltrates in skeletal muscle
tissue [1,2]. Polymyositis (PM) and dermatomyositis (DM)
are two common subsets of IIM. Although the pathological* Correspondence: guochunwang@hotmail.com
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reproduction in any medium, provided the ormechanism of IIM remains unclear, recent studies suggest
that an interplay between adaptive immune, innate im-
mune, and nonimmune mechanisms may be responsible
for the damage and dysfunction that occur in myopathic
muscle tissue [3]. Multiple players - such as adaptive im-
mune cells [4], cytokines and chemokines [5-7] - may be
involved in the pathogenesis of IIM.
Tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) is a recently identified pro-inflammatory
cytokine belonging to the TNF superfamily [8]. TWEAK
has emerged as a multifunctional cytokine that regulates
multiple cellular responses, including pro-inflammatorytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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migration and apoptosis [9]. The only known signaling
receptor for TWEAK is fibroblast growth factor-inducible
14 (Fn14), which was first recognized by differential
display technique [10]. TWEAK exerts pleiotropic func-
tions through binding to Fn14 and activating downstream
signaling pathways. Fn14 is a type I transmembrane
protein and is highly inducible by various growth factors,
including epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), and vascular endothelial growth
factor (VEGF). Fn14 is predominantly expressed on the
surface of epithelial cells, endothelial cells and other
non-hematopoietic cells [9,11].
TWEAK was found to activate nuclear factor-кB (NF-кB)
and mitogen-activated protein kinase (MAPK) signaling
pathways and to reduce MyoD levels in cultured myo-
blasts [12,13], thereby inducing the proliferation of myo-
blasts and inhibiting their differentiation into myotubes
[13]. In addition, several studies have demonstrated that
the TWEAK-Fn14 axis plays a crucial role in muscle atro-
phy [14-16]. According to the findings of Bhatnagar et al.,
TWEAK causes myotube atrophy by stimulating the
activity of the ubiquitin-proteasome system, autophagy
and caspases [15]. Coincidentally, Alger et al. reported the
expression of autophagic genes (beclin and LC3) at the
protein level in PM/DM muscle biopsy specimens but not
in healthy controls, suggesting the potential role of auto-
phagy in mediating muscle fiber death in myositis [17].
Considering the role of TWEAK in stimulating auto
phagy and impairing myogenesis, we hypothesized that
the TWEAK-Fn14 axis may be involved in the patho-
mechanism of PM/DM and set out to study whether
TWEAK-Fn14 participates in the pathogenesis of PM/DM.
Additionally, increased levels of TWEAK were found in
many types of autoimmune diseases, such as rheumatoid
arthritis [18], systemic sclerosis [19], and systemic lupus
erythematosus [20], suggesting a crucial role of TWEAK
in autoimmune disorder. However, information about
TWEAK-Fn14 expression in PM and DM is limited.
Therefore, in order to further explore the role of
TWEAK in the pathogenesis of PM/DM, we investigated
the levels of circulating TWEAK in sera and the expres-
sion of TWEAK and Fn14 in the muscle tissues of
patients with PM/DM at the mRNA and protein levels.
Methods
Patients
From the inpatients and outpatients who visited China-
Japan Friendship Hospital between 2009 and 2012, 98
patients with PM/DM were recruited for this study.
Their diagnoses of PM/DM were based on the Bohan
and Peter criteria [21]. Additionally, 37 healthy, age-
matched and sex-matched volunteers were selected to
be the healthy control group during the same timeperiod. Muscle tissues from 10 trauma patients without
muscle disease were used as normal controls for exa-
mination of TWEAK and Fn14 in muscle tissue. For
each individual patient, serum sampling and disease ac-
tivity evaluation were done at the same time. For pa-
tients who carried out muscle biopsy in our department,
muscle biopsy was also done at the time of serum sam-
pling. This study was performed with the approval of the
Human Ethics Board of China-Japan Friendship Hospital
(Beijing, China). Written informed consent was obtained
from all participating individuals.
Measurement of serum TWEAK levels and serum
CD163 levels
Fresh venous blood samples were centrifuged shortly after
clot formation, and serum samples were collected. All
samples were stored at -70°C before use. TWEAK was de-
tected in the sera of 98 PM/DM patients and 37 healthy
controls using a commercially available ELISA kit (Bender
MedSystems, Vienna, Austria). The assays were performed
according to the manufacturer’s protocol. Briefly, 100 μl
distilled water were added to all standard wells, blank wells
and sample wells, then 50 μl of each sample, in duplicate,
were added to the designated wells. After incubating at
room temperature for 3 hours, the plates were washed and
incubated with 100 μl of 3,3′,5,5′-tetramethylbenzidine
(TMB) substrate solution. About 10 minutes later, stop
solution was added, and absorbance was measured using
the ELISA reader at 450 nm with 630 nm as the reference
wavelength. A standard curve for each assay was gene-
rated, and serum TWEAK concentration was calculated.
The assays for each sample were performed three times.
Serum CD163 levels were measured by using a quantita-
tive ELISA kit (R&D Systems, Minneapolis, MN, USA).
The assays were performed according to the manufac-
turer’s protocol. Each sample was measured three times.
Assessment of disease activity
Disease activity was measured by the 2005 myositis dis-
ease activity assessment tool (MDAAT) established by the
International Myositis Assessment and Clinical Studies
(IMACS) group [22], which consists of the myositis dis-
ease activity assessment visual analog scales (MYOACT)
and the myosits intention-to-treat index (MITAX). In the
previous studies, our data showed that the MYOACT
could be used to reliably evaluate disease activity in
Chinese patients with PM/DM [23]. Therefore, we used
MYOACT to evaluate the disease activity of PM/DM
patients following the guidelines for physician scoring of
disease activity.
Real time RT-PCR
Total RNA was isolated from fresh-frozen muscle tissue
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
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RNA was reverse transcribed using the GoTaq® 2-Step
RT-qPCR system (Promega, Madison, WI, USA) according
to the manufacturer’s protocol. Fluorescent quantitative
reverse transcription polymerase chain reaction (RT-PCR)
was performed using the ABI PRISM 7500 system (Applied
Biosystems, Foster City, USA) according to standard
methods. The following primers were used for amplifying
TWEAK, Fn14 and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH): TWEAK, forward: 5′-CCCTGCGCTG
CCTGGAGGAA-3′, reverse: 5′-AGACCAGGGCCCC
TCAGTGA-3′; Fn14, forward: 5′-CCAAGCTCCTCCA
ACCACAA-3′, reverse: 5′-TGGGGCCTAGTGTCAAGT
CT-3′; GAPDH forward: 5′-ATCACCATCTTC CAG
GAGCGA-3′, reverse: 5′- CCTTCTCCATGGTGGTG
AAGAC-3′. Real time RT-PCR for TWEAK, Fn14 and
GAPDH was conducted in triplicate for each sample. The
GAPDH gene was used as an internal control: 2−Δ CT was
used to compute the expression value of target genes.
Hematoxylin and eosin staining of muscle sections
H&E staining was applied on serial cryostat muscle
biopsy sections according to the following steps. The
muscle sections were stained with Harris Hematoxylin
(Sigma-Aldrich, St Louis, MO, USA) for 5 minutes. After
rinsing in running tap water for 20 minutes, the muscle
sections were immersed in working eosin solution for
2 minutes. At last, the muscle sections underwent the
dehydration of gradient ethanol, the transparency of
dimethylbenzene, and then were mounted with Canada
balsam (Sigma-Aldrich).
Immunofluorescence staining of muscle sections
8-μm-thick unfixed cryostat muscle sections were col-
lected from diagnostic muscle biopsies. Anti-human
TWEAK polyclonal antibodies (R&D systems) and anti-
human Fn14 monoclonal antibodies (R&D systems) were
used as primary antibodies for detecting TWEAK and
Fn14 at a working concentration of 15 μg/ml. Rhodamine-
conjugated anti-goat IgG (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was used as a secondary antibody.
In summary, immunofluorescence staining was conducted
according to the following steps: muscle sections were
fixed with pre-cooled acetone at -20°C for 30 minutes and
then rinsed four times in phosphate-buffered solution.
Then, the tissue sections were blocked in 10% normal
serum with 1% BSA in tris-buffered saline (TBS) for
2 hours at room temperature. After draining for a few se-
conds, primary antibodies diluted in TBS were applied to
the tissue sections. After incubating overnight at 4°C, the
tissue sections were treated with rhodamine-conjugated
anti-goat IgG. This was followed by washing, mounting
on glass slides, and visualization of fluorescence with an
Olympus fluorescent microscope. An isotype-matched,non-binding antibody (normal goat IgG: sc-2028, Santa
Cruz Biotechnology) was used as a negative control for
the primary antibody. Two sections per tissue sample
were used for immunofluorescence staining analysis.
When double staining was carried out, anti-human
TWEAK goat polyclonal antibodies (R&D systems) and
anti-human Fn14 rabbit monoclonal antibodies (Abcam,
Cambridge, UK) were used as primary antibodies for de-
tecting TWEAK and Fn14, and Rhodamine-conjugated
donkey anti-goat IgG and FITC-conjugated donkey anti-
rabbit IgG (both from Santa Cruz Biotechnology) were
used as secondary antibodies.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
V.4.03 (GraphPad Software, San Diego, USA) and SPSS
V.16.0 (SPSS, Chicago, USA). Quantitative variables were
described as mean ± SD. Nonparametric distribution data
were expressed as median value and IQR, and the data of
unpaired samples were analyzed using the Mann-Whitney
U-test. Spearman’s correlation analysis was used to test for
correlation. The Wilcoxon signed rank test was used on
paired data when appropriate. A P-value equal to or less
than 0.05 was considered statistically significant.
Results
Clinical characteristics of PM/DM patients
The clinical features presented by the 98 patients who were
recruited for this study are summarized in Table 1. Accord-
ing to criteria established by Bohan and Peter [21], 41 pa-
tients were diagnosed with PM, and the other 57 patients
were diagnosed with DM. The mean age of these patients
at onset of PM/DM was 50.6 years. There were more fe-
males than males in the cohort. The mean duration of dis-
ease was 5.3 years (range from 1.3 to 28.0 years). Twenty
patients were examined as anti-Jo-1 antibody-positive at
the time of blood sampling for the present study.
In our cohort, 41 patients were newly diagnosed in our
department, while the other 57 patients had been diag-
nosed with PM/DM and received different treatments be-
fore they were referred to our hospitial. The treatments
received by the patients in our cohort varied according to
the severity of their disease. All patients received cortico-
steroid at doses between 0.5 mg/kg and 1 mg/kg as part of
their initial therapy after their diagnosis of PM/DM.
Meanwhile, about 80% of our patients (78 out of 98) also
received at least one or more immunosuppressants,
among which were methotrexate, cyclophosphamide, aza-
thioprine, intravenous immunoglobulin, hydroxychloro-
quine and mycophenolate mofetil.
Lower serum levels of TWEAK in patients with PM/DM
Serum levels of TWEAK were measured in 98 patients
with PM/DM. The ELISA kit used in this study can
Table 1 Demographic and clinical features of PM/DM patients and healthy controls
PM/DM patients Healthy controls
Age of onset, mean ± SD (range) years 50.6 ± 17.4 (21.5 to 75.0) 51.4 ±9.4 (27 to 70)
Number of females/number of males 77/21 27/10
Number of PM patients/number of DM patients 41/57 NA
Duration of disease, mean ± SD (range) years 5.3 ± 7.6 (1.3 to 28.0) NA
Clinical features, number of patients affected (% of cohort)
Interstitial lung disease 50 (51.0%) NA
Oropharyngeal dysphagia 35 (35.7%) NA
Raynaud’s phenomenon 20 (20.4%) NA
Mechanic’s hands 12 (12.2%) NA
Arthritis 45 (45.9%) NA
Anti-Jo-1-positive at time of blood sampling 20 (20.4%) NA
Levels of creatine kinase at initial visit, mean ± SD 1437.2 ± 1536.5 NA
PM, polymyositis; DM, dermatomyositis; NA, not applicable.
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median value of serum TWEAK concentration in PM/DM
patients was 442 pg/ml (range 81 to 1385 pg/ml), while the
median value of that in healthy controls was 516 pg/ml
(range 282 to 797 pg/ml). Therefore, serum levels of
TWEAK were significantly lower in PM/DM patients
compared to that in healthy controls (P <0.001). In
addition, serum levels of TWEAK showed no statistical
difference between PM and DM patients (P >0.05), as
shown in Figure 1A. Among the 98 PM/DM patients in
our cohort, 41 patients were newly diagnosed therefore
the serum samples of these patients were collected before
they received treatment. The other 57 patients were re-
ferred to our department, and they had received cortico-
steroids and other immunosuppressive treatment before
we collected serum samples from them. However, we did
not find a significant difference in serum TWEAK levels
between these two groups of PM/DM patients (P >0.05),
as shown in Figure 1B.
We analyzed the correlation between serum TWEAK
levels and clinical parameters. However, no significant
differences were observed when TWEAK levels were
compared in patients with PM/DM sub-grouped based on
ANA positivity (Figure 1C), Jo-1 positivity (Figure 1D),
presence of interstitial lung disease (ILD) (Figure 1E) and
presence of oropharyngeal dysphagia (Figure 1F). What is
more, no correlation was found between serum TWEAK
levels and MYOACT global disease activity scores in
42 PM/DM patients (Figure 1G) or MYOACT muscle dis-
ease activity (Figure 1H). In our study cohort, 12 patients
were newly diagnosed, and their serum samples before
and after treatment were collected. After treatment, all the
12 patients were considered as in remission stage and
their MYOACT global disease scores were significantly
decreased (P <0.01), as shown in Figure 1I. However, byapplying the Wilcoxon signed rank test, no significant dif-
ference was observed in the patients’ serum TWEAK
levels before and after treatment (P >0.05), as shown in
Figure 1J.
As some studies have revealed that CD163 expressed by
monocytes could act as a TWEAK scavenger in patho-
logical conditions [24], we detected the serum levels of
CD163 in PM/DM patients and healthy controls. Interes-
tingly, we found that serum CD163 levels were significantly
higher in PM/DM patients (median value/IQR 770.0 ng/ml,
range 212.6 to 2033.1 ng/ml) compared to healthy
controls (median value/IQR 544.0 ng/ml, range 313.0 to
859.8 ng/ml) (P <0.01) (Figure 1K), and serum CD163
levels were found to be negatively correlated (r = −0.49,
P <0.001) with serum TWEAK levels in PM/DM patients
(Figure 1L).
Increased expression of Fn14 mRNA in muscle tissue of
patients with PM/DM
The expression of TWEAK and Fn14 mRNA in the
muscle tissue of 17 PM, 19 DM patients and of 10
healthy controls was analyzed by real time RT-PCR. The
diagnoses of the 36 PM/DM patients were confirmed by
pathological diagnoses of muscle biopsies. The expres-
sion of TWEAK mRNA in the muscle tissue of patients
with PM/DM was not significantly different from that of
the healthy controls (P >0.05) (Figure 2A). However, the
expression of Fn14 mRNA was significantly higher in
the muscle tissue of PM/DM patients than in the healthy
controls (P <0.01) (Figure 2B). The Fn14 mRNA levels
showed no significant difference between PM and DM
patients (P >0.05) (Figure 2B). Interestingly, we found
that patients with oropharyngeal dysphagia had signifi-
cantly higher Fn14 mRNA levels than the patients with-
out oropharyngeal dysphagia (Figure 2C). In addition,
Figure 1 Serum levels of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in patients with polymyositis (PM)/dermatomyositis
(DM) and in healthy controls. Serum TWEAK levels were determined by a specific ELISA. TWEAK levels in healthy subjects were compared to
patienta with PM or DM (A). There was no statistical difference in serum TWEAK levels between patients previously untreated and patients who
received treatments (B). No significant differences were observed when TWEAK levels were compared in patients with PM/DM sub-grouped
based on antinuclear antibody (ANA) positivity (C), Jo-1 positivity (D), presence of interstitial lung disease (ILD) (E) and presence of oropharyngeal
dysphagia (F). Correlation of serum levels of TWEAK with myositis disease activity assessment visual analog scales (MYOACT) global disease activity
(G) and MYOACT muscle disease activity (H) were analyzed. Twelve newly diagnosed PM/DM patients had significantly decreased MYOACT global
disease scores after treatment (I), however, no significant difference was observed in the patients’ serum TWEAK levels before and after treatment
(J). Serum CD163 levels were determined by a quantitative ELISA. Serum CD163 levels were significantly higher in PM/DM patients compared to
healthy controls (K), and serum CD163 levels were found to be negatively correlated with serum TWEAK levels in PM/DM patients (L). The data
for unpaired samples were analyzed by using the Mann-Whitney U-test. Spearman’s correlation analysis was used to test for correlation. The
Wilcoxon signed rank test was used on paired data. Horizontal bars indicate median levels.
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muscle disease activity scores (r = 0.512, P <0.01), but
did not correlate with MYOACT global disease activity
score (P >0.05), as shown in Figure 2D and Figure 2E
respectively.
High expression of TWEAK and Fn14 protein in PM/DM
muscle biopsies
We analyzed the expressions of TWEAK and Fn14 in the
muscle biopsies of 13 patients with DM, 10 patients with
PM, and 7 healthy controls using immunofluorescence
staining. The diagnoses of the 23 PM/DM patientsreceived pathological confirmation. As shown in Table 2,
strong expressions of TWEAK were observed in 8 of the
10 PM patients and in 11 of the 13 DM patients; none
of the healthy controls showed obvious expression of
TWEAK in muscle biopsies. Similarly, the results of im-
munofluorescence staining showed remarkable expression
of Fn14 in 8 of the 10 PM patients and in 12 of the 13
DM patients; there was no significant expression of Fn14
in any of the healthy controls. Additionally, all patients
who were Fn14-negative also showed no detectable
TWEAK expression. However, the muscle biopsy of one
DM patient stained positive for Fn14 but stained negative
Figure 2 Comparison of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Fn14 mRNA levels of polymyositis (PM)/
dermatomyositis (DM) and of healthy controls. Total RNA was isolated from fresh-frozen muscle tissue using TRIzol reagent, and fluorescent
quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
was used as an internal control. 2−Δ CT was used to compute the expression values of the target genes. (A) TWEAK mRNA levels in muscle tissue of
PM, DM and healthy controls. (B) Fn14 mRNA levels in muscle tissue of PM, DM and healthy controls. (C) Fn14 mRNA levels were compared in
PM/DM patients sub-grouped based on the presence of oropharyngeal dysphagia. (D) Correlation of Fn14 mRNA levels with myositis disease activity
assessment visual analog scales (MYOACT) muscle disease activity scores. (E) Correlation of Fn14 mRNA levels with MYOACT global disease activity
scores. The data of unpaired samples were analyzed by using the Mann-Whitney U-test. Spearman’s correlation analysis was used to test for
correlations. Horizontal bars indicate median levels.
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sentative results of immunofluorescence staining of the
muscle biopsies. Muscle biopsies from the healthy con-
trols showed no significant TWEAK or Fn14 expression.
And no obvious immunofluorescence signal was observed
in PM/DM muscle biopsies staining with isotype control
antibody.
Additionally, in order to analyze TWEAK expression
relative to muscle pathology, we conducted H&E staining
on serial muscle biopsy sections. Figure 3C showed the
same type of field on TWEAK immunofluorescenceTable 2 PM/DM patients with positive immunofluorescence st
PM patients
TWEAK positive (number/number assessed) 8/10
Fn14 positive (number/number assessed) 8/10
TWEAK, tumor necrosis factor-like weak inducer of apoptosis; PM, polymyositis; DMstaining and H&E staining. We observed a remarkably
strong expression of TWEAK in the field where abundant
infiltrating monocytes existed. TWEAK immunoreactivity
was also observed around the sarcolemma of muscle fibers
partially invaded or surrounded by monocytes, and mem-
brane TWEAK staining was also visible in a large number
of fibers that were not near inflammatory cells.
To further demonstrate the localization of the TWEAK
and Fn14 protein, we carried out double staining for
TWEAK and Fn14. As shown in Figure 3D, the expression
of TWEAK was dramatically observed around theaining for TWEAK and Fn14




Figure 3 (See legend on next page.)
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Figure 3 Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Fn14 in patients with polymyositis (PM)/
dermatomyositis (DM) and in healthy controls. (A) Muscle biopsies from patients with PM/DM showed significantly higher levels of the
TWEAK protein compared to those of healthy controls. Anti-human TWEAK polyclonal antibodies were used as the primary antibody for detection
at a working concentration of 15 μg/ml. Rhodamine-conjugated anti-goat IgG was used as a second antibody. (B) In PM/DM biopsies, expression
of the Fn14 protein was remarkably higher than that of healthy controls. Anti-human Fn14 monoclonal antibodies were used as the primary
antibody for detection at a working concentration of 15 μg/ml. Rhodamine-conjugated anti-goat IgG was used as a second antibody. Each muscle
section was analyzed in duplicate, and results from one representative experiment are shown. Negative controls were conducted by staining muscle
biopsies with isotype control antibody, and no obvious immunofluorescence signal was observed in negative controls. (C) Serial muscle biopsy
sections of PM/DM patients were applied for TWEAK immunofluorescence staining and H&E staining, and a representative picture of the same type of
field is shown. (D) Muscle biopsy sections of PM/DM patient were applied for TWEAK and Fn14 immunofluorescence staining and a representative
staining is shown. To ensure comparability, images were obtained using identical exposure settings for each channel. The TWEAK immunoreactivity is
predominantly observed around the infiltrating monocytes, and a mild expression of TWEAK on the sarcolemma of muscle fibers is also visible. While
Fn14 are mainly expressed on the sarcolemma of muscle fibers. Therefore, TWEAK and Fn14 are frequently found to be coexpressed in the same
myofibers on overlay images. Magnification is 200 ×.
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on the sarcolemma of muscle fibers was also visible,
whereas Fn14 was mainly expressed on the sarcolemma of
muscle fibers. We therefore found that TWEAK and Fn14
are frequently coexpressed in the same myofibers on over-
lay images (Figure 3D, merge). This was probably due to
the soluble TWEAK protein secreted by inflammatory
cells that could bind to the Fn14 expressed on the sarco-
lemma of muscle fibers.
Discussion
In this study, we found a significantly lower level of serum
TWEAK and a statistically higher level of serum CD163
in PM/DM patients compared to those in healthy con-
trols. Serum CD163 levels were found to be negatively
correlated with serum TWEAK levels in PM/DM patients.
Relative quantification mRNA analysis showed that Fn14
mRNA expression in the muscle tissue of PM/DM pa-
tients was higher than in healthy controls, and Fn14
mRNA levels positively correlated with MYOACT muscle
disease activity scores. However, there was no significant
difference between the TWEAK mRNA expressions in the
muscle tissue of PM/DM patients and of healthy controls.
We also examined expressions of TWEAK and Fn14 in
muscle biopsy specimens at the protein level and found
that TWEAK and Fn14 expressions were significantly in-
creased in PM/DM patients.
Serum levels of TWEAK were found to be elevated in
rheumatoid arthritis [25] and systemic sclerosis [19].
In patients with systemic lupus erythematosus, urinary
TWEAK level was found to be increased [26], but contro-
versial results were obtained when serum TWEAK levels
in systemic lupus erythematosus were investigated [26,27].
These findings suggest that TWEAK probably plays
an important pathogenic role in autoimmune disorders
[28,29]. However, in our study, we found that serum levels
of TWEAK in PM/DM patients were significantly lower
compared to those in healthy controls. We analyzedserum levels of TWEAK in 98 patients with PM/DM, and
each sample was measured three times. Therefore, pos-
sible bias resulting from sample size is reduced. The inter-
esting finding of lower serum TWEAK levels in PM/DM
patients prompted us to find a reasonable explanation. Re-
cently, it has been shown that CD163 can specifically bind
and neutralize TWEAK [24] and that CD163-expressing
monocytes/macrophages are able to bind and internalize
exogenous TWEAK [30]. Taking into account molecular
interaction between TWEAK and CD163 molecules, in
the present study we evaluated serum CD163 levels in
PM/DM patients, and we found a negative correlation bet-
ween serum levels of TWEAK and CD163. These results
probably gave a good explanation for the lower serum
levels of TWEAK in PM/DM patients. Although the role
of the serum TWEAK- CD163 interaction in PM/DM
pathogenesis remains to be elucidated, our findings sug-
gest a potential role of serum TWEAK and CD163 mole-
cules in PM/DM.
Our further research showed that TWEAK expression
at the protein level was remarkably increased in the
muscle tissue of PM/DM patients, but TWEAK expres-
sion at the mRNA level showed no statistical difference
with that of healthy controls. As we know, leukocytes are
the major source of TWEAK [9], and muscle cells are un-
likely to express the TWEAK protein. Because most of the
mRNA extracted from muscle tissues was derived from
muscle cells, it is reasonable that TWEAK mRNA levels
showed no difference between PM/DM patients and
healthy controls. In addition, we analyzed TWEAK im-
munofluorescence staining relative to H&E staining on
serial biopsy sections. We observed a remarkably strong
expression of TWEAK in the field where abundant infil-
trating monocytes existed. Moreover, we carried out
double staining for TWEAK and Fn14 on muscle biopsy
sections to demonstrate the localization of the TWEAK
and Fn14 protein, and the result showed that the TWEAK
immunoreactivity was predominantly observed around
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TWEAK on the sarcolemma of muscle fibers was also
visible, whereas Fn14 was mainly expressed on the sarco-
lemma of muscle fibers. Therefore, it is probable that the
marked evidence of TWEAK protein in the muscle tissues
of PM/DM patients was not due to expression by muscle
cells but was a product of locally infiltrating leukocytes,
which was secreted by inflammatory cells and bound to
the Fn14 expressed on the sarcolemma of muscle fibers.
In the study of Mustonen et al., TWEAK and Fn14 ex-
pression were assessed in experimental models of cardiac
remodeling, and the results showed that the mRNA and
protein levels of Fn14 were significantly upregulated,
whereas the TWEAK mRNA and protein levels remained
almost unchanged [31]. Therefore, their study challenged
the previous assumptions of TWEAK expression in re-
sponse to injury, and provided new insights into the role
of ligand-independent Fn14 signaling in cardiac remodel-
ing [31]. In contrast to cardiac remodeling, our study
showed increased expression of TWEAK protein in locally
infiltrating leukocytes and upregulated expression of Fn14
mRNA and protein on the sarcolemma of muscle fibers.
The present study therefore suggested a possible role of
TWEAK-Fn14 signaling in the pathogenesis of PM/DM.
Aberrant expression of TWEAK and/or Fn14 has been
found to be linked with deleterious pathogenic effects in
autoimmune diseases [9]. The TWEAK cytokine and its re-
ceptor, Fn14, are identified as critical regulators of skeletal
muscle mass [9,16]. It has been proposed that TWEAK
causes Fn14 trimerization and subsequent activation of
several signaling proteins including TRAF6, transforming
growth factor-β activated kinase 1, I kappa B kinase, and
MAPK leading to the activation of various transcription
factors followed by gene expression [9,32-34]. Moreover,
Mittal et al. reported that TWEAK could suppress the re-
generation and growth of myofibers after injury and that
the expression of both TWEAK and Fn14 were increased
in skeletal muscle after injury caused by intramuscular in-
jections of cardiotoxin [35]. What is more, it is reported by
Girgenrath et al. that Fn14 is highly expressed on muscle
progenitor cells and TWEAK could inhibit myogenic dif-
ferentiation [36]. Recently, it has been demonstrated by
Enwere et al. that high concentrations of TWEAK could
activate the canonical NF-кB pathway and impair myo-
genesis [37]. Therefore, the TWEAK-Fn14 axis may con-
tribute to muscle atrophy by impairing skeletal muscle
formation. It is worth mentioning that in PM/DM, impair-
ment of muscle regeneration is also a critical characteristic
of disease progression. Our study found that Fn14 expres-
sion was higher at both mRNA and protein levels in the
muscle tissue of PM/DM patients. What is more, we ana-
lyzed the relationship between TWEAK and Fn14 expres-
sions and clinical parameters, and found that patients with
oropharyngeal dysphagia had significantly higher Fn14mRNA levels than patients who did not suffer from oro-
pharyngeal dysphagia. Furthermore, our study showed a
moderate correlation between the Fn14 mRNA levels and
muscle disease activity in PM/DM patients. Additionally,
TWEAK protein levels were also significantly elevated in
the muscle tissue of PM/DM patients, although their deriv-
ation needs to be further confirmed. Taken together, our
findings suggest that the TWEAK-Fn14 axis is probably in-
volved in the pathogenesis of PM/DM.
As stated by Morosetti et al., dysregulation of the
TWEAK-Fn14 axis in inclusion-body myositis (IBM)
muscle may play a dual role in the pathogenesis of IBM by
inducing muscle wasting and inhibiting regenerative myo-
genesis [38]. In their study, TWEAK and Fn14 expression
in the muscle tissues of six DM patients, six PM patients
and three healthy controls was analyzed by immunohisto-
chemistry. Results showed that only muscle fibers that
were invaded or surrounded by monocytes and degene-
rating fibers next to inflammatory infiltrates showed in-
creased membrane TWEAK and Fn14 immunoreactivity
[38]. Our findings seem to be inconsistent with their re-
sults. However, in our study, a larger number of patients
were analyzed for TWEAK and Fn14 expression. More
importantly, all the patients whose biopsies were exa-
mined for TWEAK and Fn14 expression by immuno-
fluorescence staining received confirmed pathological
diagnoses. On the other hand, whether these contra-
dictory findings are a result of ethnic diversity needs to be
verified by further studies.
To our knowledge, our study was the first to systema-
tically investigate the expression of TWEAK and Fn14
in a large cohort of PM/DM patients. The strength
of our study is that all the PM/DM patients whose
TWEAK and Fn14 expressions in muscle tissue were
examined received pathological diagnoses. Muscle bi-
opsy is the most crucial test for establishing the diag-
nosis of PM/DM and can be used to exclude other
neuromuscular diseases [1,39,40]. Therefore, the bias
resulting from false disease diagnoses was reduced in
our study.
However, we acknowledge that our study has some
limitations. First of all, our sample size of PM/DM pa-
tients whose expression of TWEAK and Fn14 in
muscle tissue was investigated was relatively small.
This was partly due to our strict selection only of pa-
tients who had pathologically confirmed diagnoses.
Another limitation of our study is that the expression
of TWEAK mRNA in peripheral blood lymphocytes
was not examined.
Conclusions
In conclusion, our study showed that significantly high
levels of TWEAK and Fn14 could be found in the
muscle tissue of PM/DM patients, and Fn14 mRNA
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http://arthritis-research.com/content/16/1/R26levels in muscle tissue positively correlated with muscle
disease activity. Regardless of the precise mechanism,
the TWEAK-Fn14 axis may probably be involved in the
pathogenesis of PM/DM. Further understanding of
TWEAK-Fn14 function in PM/DM may help to define
therapeutic targets for PM/DM.
Abbreviations
ANA: antinuclear antibody; BSA: bovine serum albumin; DM: dermatomyositis;
EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbent assay;
Fn14: fibroblast growth factor-inducible 14; GAPDH: glyceraldehyde-3-
phosphate dehydrogenase; H&E: hematoxylin and eosin; IBM: inclusion-body
myositis; IIM: idiopathic inflammatory myopathies; ILD: interstitial lung disease;
MAPK: mitogen-activated protein kinase; MYOACT: myositis disease activity
assessment visual analog scales; PDGF: platelet-derived growth factor;
PM: polymyositis; RT-PCR: reverse transcription polymerase chain reaction;
TBA: tris-buffered saline; TNF: tumor necrosis factor; TWEAK: tumor necrosis
factor-like weak inducer of apoptosis; VEGF: vascular endothelial growth factor.
Competing interests
The authors declare no potential conflict of interest.
Authors’ contributions
QLP and GCW contributed to study design, data collection, statistical
analysis, interpretation of data and drafting the manuscript; XMS acquired
the clinical data; XLT participated in the analysis of serum TWEAK levels; XL
participated in study design, acquisition, analysis and interpretation of data.
All authors were involved in drafting the article or revising it critically for
important intellectual content, and all authors read and approved the final
version.
Acknowledgements
This work was supported by the General Program of the National Natural
Science Foundation of China (Grant No. 81172860), and the Science and
Technology Commission Foundation of Beijing (No. Z121107001012005).
Received: 23 July 2013 Accepted: 24 January 2014
Published: 27 January 2014
References
1. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003,
362:971–982.
2. Zong M, Lundberg IE: Pathogenesis, classification and treatment of
inflammatory myopathies. Nat Rev Rheumatol 2011, 7:297–306.
3. Rayavarapu S, Coley W, Nagaraju K: An update on pathogenic
mechanisms of inflammatory myopathies. Curr Opin Rheumatol 2011,
23:579–584.
4. Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E,
Nennesmo I, Malmberg KJ, Soderberg-Naucler C, Trollmo C, Lundberg IE,
Malmström V: T cell infiltrates in the muscles of patients with dermatomyo-
sitis and polymyositis are dominated by CD28null T cells. J Immunol 2009,
183:4792–4799.
5. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA,
Greenberg SA: Type I interferon-inducible gene expression in blood is
present and reflects disease activity in dermatomyositis and polymyositis.
Arthritis Rheum 2007, 56:3784–3792.
6. Wenzel J, Scheler M, Bieber T, Tuting T: Evidence for a role of type I
interferons in the pathogenesis of dermatomyositis. Br J Dermatol 2005,
153:462–463.
7. Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA,
Krastins B, Morehouse C, Higgs BW, Jallal B, Yao Y, Sarracino DA, Parker KC,
Greenberg SA: Interferon-stimulated gene 15 (ISG15) conjugates proteins
in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010,
67:53–63.
8. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS: TWEAKing
tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14
pathway in health and disease. Cytokine 2007, 40:1–16.
9. Burkly LC, Michaelson JS, Zheng TS: TWEAK/Fn14 pathway: an
immunological switch for shaping tissue responses. Immunol Rev 2011,
244:99–114.10. Wiley SR, Cassiano L, Lofton T, Vis-Smith T, Winkles JA, Lindner V, Liu H,
Daniel TO, Smith CA, Fanslow WC: A novel TNF receptor family member
binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837–846.
11. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology
and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411–425.
12. Dogra C, Changotra H, Mohan S, Kumar A: Tumor necrosis factor-like weak
inducer of apoptosis inhibits skeletal myogenesis through sustained
activation of nuclear factor-kappaB and degradation of MyoD protein.
J Biol Chem 2006, 281:10327–10336.
13. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A: Fibroblast growth factor
inducible 14 (Fn14) is required for the expression of myogenic
regulatory factors and differentiation of myoblasts into myotubes.
Evidence for TWEAK-independent functions of Fn14 during myogenesis.
J Biol Chem 2007, 282:15000–15010.
14. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, Makonchuk DY,
Glass DJ, Kumar A: The TWEAK-Fn14 system is a critical regulator of
denervation-induced skeletal muscle atrophy in mice. J Cell Biol 2010,
188:833–849.
15. Bhatnagar S, Mittal A, Gupta SK, Kumar A: TWEAK causes myotube atrophy
through coordinated activation of ubiquitin-proteasome system,
autophagy, and caspases. J Cell Physiol 2012, 227:1042–1051.
16. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A: TNF-related
weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting
cytokine. FASEB J 2007, 21:1857–1869.
17. Alger HM, Raben N, Pistilli E, Francia DL, Rawat R, Getnet D, Ghimbovschi S,
Chen YW, Lundberg IE, Nagaraju K: The role of TRAIL in mediating
autophagy in myositis skeletal muscle: a potential nonimmune
mechanism of muscle damage. Arthritis Rheum 2011, 63:3448–3457.
18. Dharmapatni AA, Smith MD, Crotti TN, Holding CA, Vincent C, Weedon HM,
Zannettino AC, Zheng TS, Findlay DM, Atkins GJ, Haynes DR: TWEAK and
Fn14 expression in the pathogenesis of joint inflammation and bone
erosion in rheumatoid arthritis. Arthritis Res Ther 2011, 13:R51.
19. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Usui A, Hasegawa M,
Fujimoto M, Takehara K, Sato S: Elevated circulating TWEAK levels in
systemic sclerosis: association with lower frequency of pulmonary
fibrosis. J Rheumatol 2009, 36:1657–1662.
20. Liu ZC, Zhou QL, Li XZ, Yang JH, Ao X, Veeraragoo P, Zuo XX: Elevation of
human tumor necrosis factor-like weak inducer of apoptosis in peripheral
blood mononuclear cells is correlated with disease activity and lupus
nephritis in patients with systemic lupus erythematosus. Cytokine 2011,
53:295–300.
21. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts).
N Engl J Med 1975, 292:344–347.
22. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE,
Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L,
Miller F; International Myositis and Clinical Studies Group (IMACS):
International consensus outcome measures for patients with idiopathic
inflammatory myopathies. Development and initial validation of myositis
activity and damage indices in patients with adult onset disease.
Rheumatology (Oxford) 2004, 43:49–54.
23. Shu XM, Lu X, Xie Y, Wang GC: Clinical characteristics and favorable
long-term outcomes for patients with idiopathic inflammatory
myopathies: a retrospective single center study in China. BMC Neurol
2011, 11:143.
24. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB,
Arap W, Pasqualini R: A previously unrecognized protein-protein interaction
between TWEAK and CD163: potential biological implications. J Immunol
2007, 178:8183–8194.
25. Park MC, Chung SJ, Park YB, Lee SK: Relationship of serum TWEAK level to
cytokine level, disease activity, and response to anti-TNF treatment in pa-
tients with rheumatoid arthritis. Scand J Rheumatol 2008, 37:173–178.
26. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B,
Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C:
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort
study. Arthritis Res Ther 2009, 11:R143.
27. Wang C, Chen LL, Pan HF, Leng RX, Qin WZ, Ye DQ: Expression of human
tumor necrosis factor-like weak inducer of apoptosis in patients with
systemic lupus erythematosus. Clin Rheumatol 2012, 31:335–339.
28. Park JS, Park MK, Lee SY, Oh HJ, Lim MA, Cho WT, Kim EK, Ju JH, Park YW,
Park SH, Cho ML, Kim HY: TWEAK promotes the production of Interleukin-
17 in rheumatoid arthritis. Cytokine 2012, 60:143–149.
Peng et al. Arthritis Research & Therapy 2014, 16:R26 Page 11 of 11
http://arthritis-research.com/content/16/1/R2629. Zhi-Chun L, Qiao-Ling Z, Zhi-Qin L, Xiao-Zhao L, Xiao-xia Z, Rong T: Tumor
necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38
mitogen-activated protein kinase activation and signal transduction in
peripheral blood mononuclear cells from patients with lupus nephritis.
Inflammation 2012, 35:935–943.
30. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J,
Paramo JA, Ortega L, Egido J, Blanco-Colio LM: The CD163-expressing
macrophages recognize and internalize TWEAK: potential consequences
in atherosclerosis. Atherosclerosis 2009, 207:103–110.
31. Mustonen E, Sakkinen H, Tokola H, Isopoussu E, Aro J, Leskinen H, Ruskoaho H,
Rysa J: Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and
its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) 2010,
199:11–22.
32. Kumar A, Bhatnagar S, Paul PK: TWEAK and TRAF6 regulate skeletal
muscle atrophy. Curr Opin Clin Nutr Metab Care 2012, 15:233–239.
33. Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A: TNF-like weak inducer of
apoptosis (TWEAK) activates proinflammatory signaling pathways and
gene expression through the activation of TGF-beta-activated kinase 1.
J Immunol 2009, 182:2439–2448.
34. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M,
Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J:
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2
complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008, 182:171–184.
35. Mittal A, Bhatnagar S, Kumar A, Paul PK, Kuang S, Kumar A: Genetic
ablation of TWEAK augments regeneration and post-injury growth of
skeletal muscle in mice. Am J Pathol 2010, 177:1732–1742.
36. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA,
Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA,
Miller JB, Burkly LC, Zheng TS: TWEAK, via its receptor Fn14, is a novel
regulator of mesenchymal progenitor cells and skeletal muscle
regeneration. EMBO J 2006, 25:5826–5839.
37. Enwere EK, Holbrook J, Lejmi-Mrad R, Vineham J, Timusk K, Sivaraj B, Isaac M,
Uehling D, Al-Awar R, Lacasse E, Korneluk RG: TWEAK and cIAP1 regulate
myoblast fusion through the noncanonical NF-kappaB signaling pathway.
Sci Signal 2012, 5:ra75.
38. Morosetti R, Gliubizzi C, Sancricca C, Broccolini A, Gidaro T, Lucchini M,
Mirabella M: TWEAK in inclusion-body myositis muscle: possible
pathogenic role of a cytokine inhibiting myogenesis. Am J Pathol 2012,
180:1603–1613.
39. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis.
N Engl J Med 1991, 325:1487–1498.
40. Dalakas MC: Muscle biopsy findings in inflammatory myopathies.
Rheum Dis Clin North Am 2002, 28:779–798.
doi:10.1186/ar4454
Cite this article as: Peng et al.: Expression of tumor necrosis factor-like
weak inducer of apoptosis and fibroblast growth factor-inducible 14 in
patients with polymyositis and dermatomyositis. Arthritis Research &
Therapy 2014 16:R26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
